The result of Allergan PLC’s board-directed strategic review is a plan to divest its women’s health and infectious disease units – narrowing the company's focus to four primary therapeutic areas – but it isn’t time yet to consider splitting off aesthetics into a separate business, CEO Brent Saunders said May 30.
Saunders stressed that Allergan does not need to sell off any business segments and is not undertaking a fire sale...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

